In a new study, the OMRF compound OKN-007 is being combined with the current standard-of-care medication for glioblastoma.
chemo
Q BioMed Inc. finalizes license agreement with OMRF, RGCB
QBioMed has the global exclusive rights to develop and market a novel chemotherapeutic drug to treat liver cancer.